In a phase II randomized 3‐month study with 2‐year adjuvant afatinib in surgically resected stage I–III NSCLC patients harboring EGFR mutation, 2‐year DFS was increased by 14% in patients treated for 2 years compared to those who were treated for 3 months (85% vs. 71%).34 Here, EGFR is linked to non-small cell lung carcinoma.